Jonathan Wolleben
Stock Analyst at Citizens
(4.59)
# 236
Out of 5,147 analysts
239
Total ratings
53.85%
Success rate
27.99%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $167 → $176 | $92.73 | +89.80% | 7 | Feb 27, 2026 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $120 → $113 | $62.98 | +79.42% | 12 | Feb 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $102 → $112 | $92.08 | +21.63% | 14 | Feb 26, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $140 → $132 | $92.29 | +43.03% | 14 | Feb 26, 2026 | |
| SION Sionna Therapeutics | Initiates: Market Outperform | $63 | $36.54 | +72.41% | 1 | Feb 24, 2026 | |
| QNCX Quince Therapeutics | Downgrades: Market Perform | n/a | $0.13 | - | 3 | Jan 30, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $527 → $745 | $432.00 | +72.45% | 15 | Jan 20, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $108 → $105 | $41.10 | +155.47% | 18 | Jan 8, 2026 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $21 → $45 | $20.99 | +114.39% | 16 | Dec 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $33 → $35 | $5.71 | +512.96% | 9 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $11 → $10 | $6.02 | +66.11% | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $254 → $259 | $54.94 | +371.42% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $28 | $16.28 | +71.99% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $4.31 | +224.83% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $8.75 | +185.71% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $10.46 | +91.20% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $8.94 | +224.38% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $5.31 | +238.98% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $28.39 | +83.16% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.59 | +403.14% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $0.74 | +1,913.69% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $5.89 | +222.58% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $32.55 | +16.74% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $44.96 | +11.21% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $44.63 | +101.66% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $135.11 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $503.90 | -3.75% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $64 | $7.54 | +748.81% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $28.60 | -16.08% | 1 | May 12, 2023 |
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Market Outperform
Price Target: $167 → $176
Current: $92.73
Upside: +89.80%
Structure Therapeutics
Feb 27, 2026
Maintains: Market Outperform
Price Target: $120 → $113
Current: $62.98
Upside: +79.42%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Market Outperform
Price Target: $102 → $112
Current: $92.08
Upside: +21.63%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $140 → $132
Current: $92.29
Upside: +43.03%
Sionna Therapeutics
Feb 24, 2026
Initiates: Market Outperform
Price Target: $63
Current: $36.54
Upside: +72.41%
Quince Therapeutics
Jan 30, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.13
Upside: -
Madrigal Pharmaceuticals
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $432.00
Upside: +72.45%
Crinetics Pharmaceuticals
Jan 8, 2026
Maintains: Market Outperform
Price Target: $108 → $105
Current: $41.10
Upside: +155.47%
DBV Technologies
Dec 17, 2025
Maintains: Market Outperform
Price Target: $21 → $45
Current: $20.99
Upside: +114.39%
Sagimet Biosciences
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $5.71
Upside: +512.96%
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $6.02
Upside: +66.11%
Nov 11, 2025
Maintains: Market Outperform
Price Target: $254 → $259
Current: $54.94
Upside: +371.42%
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $16.28
Upside: +71.99%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $4.31
Upside: +224.83%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $8.75
Upside: +185.71%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $10.46
Upside: +91.20%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $8.94
Upside: +224.38%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $5.31
Upside: +238.98%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $28.39
Upside: +83.16%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.59
Upside: +403.14%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $0.74
Upside: +1,913.69%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $5.89
Upside: +222.58%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $32.55
Upside: +16.74%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $44.96
Upside: +11.21%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $44.63
Upside: +101.66%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $135.11
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $503.90
Upside: -3.75%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $64
Current: $7.54
Upside: +748.81%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $28.60
Upside: -16.08%